Office Action Predictor
Last updated: April 16, 2026
Application No. 17/898,960

PSYCHOLOGICAL FATIGUE PREVENTER OR IMPROVER

Final Rejection §102
Filed
Aug 30, 2022
Examiner
CHEN, CATHERYNE
Art Unit
1655
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Fujicco Co., LTD.
OA Round
2 (Final)
37%
Grant Probability
At Risk
3-4
OA Rounds
4y 3m
To Grant
55%
With Interview

Examiner Intelligence

Grants only 37% of cases
37%
Career Allow Rate
284 granted / 769 resolved
-23.1% vs TC avg
Strong +18% interview lift
Without
With
+18.4%
Interview Lift
resolved cases with interview
Typical timeline
4y 3m
Avg Prosecution
48 currently pending
Career history
817
Total Applications
across all art units

Statute-Specific Performance

§101
13.5%
-26.5% vs TC avg
§103
40.3%
+0.3% vs TC avg
§102
21.3%
-18.7% vs TC avg
§112
16.6%
-23.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 769 resolved cases

Office Action

§102
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION The Amendments filed on Sept. 10, 2025 has been received and entered. Claims 1-5 and 7-10 are pending and examined on the merits. Election/Restrictions Applicant’s election without traverse of the species mental fatigue in the reply filed on Feb. 18, 2025 is acknowledged. Information Disclosure Statement The information disclosure statement (IDS) submitted on 1/20/23, 5/25/23, 8/23/23, 2/14/24, 8/22/24, 3/10/25 are in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Response to Amendment Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1-5 and 7-10 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Sakimoto et al. (JP 2005261237 A). This is a new rejection. Sakimoto et al. teaches a method of improving food effective for improving asthenopia with black soybean seed coat extract composition extracted from black soybean seed coat used as the main ingredient for improving eyestrain and stiff shoulders (Abstract, Background Art). Black soybean seed coat extract contains anthocyanin compounds, which are plant pigments, and contains a lot of cyanidin 3-glucoside, which is said to be highly active, and it causes eye fatigue, dry eyes, headache and stiff shoulders. It has the effect of improving eye strain represented by symptoms (Tech Solution, paragraph 3). Headache is a mental stress. Black soybean seed coat extraction solvent at pH 1-5. Acids to be adjusted to pH 1 to 5 include inorganic acids (hydrochloric acid, sulfuric acid, etc.) or organic acids (formic acid, acetic acid, citric acid, ascorbic acid, etc.), and extraction solvents are water (Best-Mode, paragraph 4). The same extraction solvent and ingredient are used in the same way; therefore, the composition would inherently contain the same compounds in the same amounts as in Claim 1. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CATHERYNE CHEN whose telephone number is (571)272-9947. The examiner can normally be reached Monday-Friday 9-5:30 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anand U Desai can be reached at 571-272-00947. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Catheryne Chen Examiner Art Unit 1655 /ANAND U DESAI/Supervisory Patent Examiner, Art Unit 1655
Read full office action

Prosecution Timeline

Aug 30, 2022
Application Filed
May 14, 2025
Non-Final Rejection — §102
Sep 10, 2025
Response Filed
Jan 05, 2026
Final Rejection — §102
Apr 06, 2026
Response after Non-Final Action

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12589184
CLINICAL DRESSING LOADED WITH COFFEE EXTRACT
2y 5m to grant Granted Mar 31, 2026
Patent 12569424
STABLE VITAMIN C COMPOSITIONS
2y 5m to grant Granted Mar 10, 2026
Patent 12551521
COMPOSITIONS INCLUDING PINE BARK EXTRACT, BERRYFRUIT EXTRACT AND A SOURCE OF L-THEANINE AND USES THEREOF
2y 5m to grant Granted Feb 17, 2026
Patent 12551520
MAQUI BERRY EXTRACTS FOR TREATMENT OF SKIN DISEASES
2y 5m to grant Granted Feb 17, 2026
Patent 12544352
DIAPER CREAM
2y 5m to grant Granted Feb 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
37%
Grant Probability
55%
With Interview (+18.4%)
4y 3m
Median Time to Grant
Moderate
PTA Risk
Based on 769 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in for Full Analysis

Enter your email to receive a magic link. No password needed.

Free tier: 3 strategy analyses per month